Thrive raises $257M Series B round for registration study of blood test for early cancer detection July 29, 2020 Auto Bot biopharma nl, Cambridge, cancer, Diagnostics, Lux Capital, Massachusetts, Oncology, Startups 0 The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.